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Abstract
Purpose The Sleep Position Trainer (SPT) is a new option for
treating patients with positional obstructive sleep apnea
(POSA). This study investigated long-term efficacy, adher-
ence, and quality of life during use of the SPT device com-
pared with oral appliance therapy (OAT) in patients with
POSA.
Methods This prospective, multicenter trial randomized pa-
tients with mild to moderate POSA (apnea-hypopnea index
[AHI] 5–30/h) to SPT or OAT. Polysomnography was per-
formed at baseline and after 3 and 12 months’ follow-up.
The primary endpoint was OSA severity; adherence, quality
of life, and adverse events were also assessed.
Results Ninety-nine patients were randomized and 58 com-
pleted the study (29 in each group). Median AHI in the SPT
group decreased from 13.2/h at baseline to 7.1/h after
12 months (P < 0.001); corresponding values in the OAT
group were 13.4/h and 5.0/h (P < 0.001), with no significant
between-group difference (P = 1.000). Improvements
throughout the study were maintained at 12 months. Long-
term median adherence was also similar in the two treatment
groups; the proportion of patients who used their device for
≥ 4 h for 5 days in a week was 100% in the SPT group and
97.0% in the OAT group (P = 0.598).
Conclusions The efficacy of SPT therapy was maintained
over 12months and was comparable to that of OAT in patients
with mild to moderate POSA. Adherence was relatively high,
and similar in the two groups.
Trial registration: www.clinicaltrials.gov (NCT02045576).
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Introduction
Obstructive sleep apnea (OSA) is the most common sleep-
related breathing disorder. With an overall prevalence of 9–
38% in the general adult population, OSA is more common in
men and increases with age [1]. Recent data from Switzerland
showed that OSAwas more prevalent than previously report-
ed. The proportion of men and women with an apnea-
hypopnea index (AHI) of > 5/h on polysomnography (PSG)
was 84 and 61%, respectively [2]. An AHI of ≥ 5/h is required
for a diagnosis of OSA, with disease severity rated as mild if
the AHI is 5–15/h, moderate if the AHI is 15–30/h, and severe
if the AHI is > 30/h [3].
OSA is characterized by recurrent (partial) obstruction of
the upper airway, accompanied by oxygen desaturation, sleep
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disturbance, and sympathetic activation [4]. Consequences of
OSA include excessive daytime sleepiness, reduced quality of
life, and increased risk of developing cardiovascular disease.
More than half of the OSA population (56%), and predomi-
nantly those with mild and moderate OSA, have position-
dependent OSA (POSA) with more apneic and hypopneic
events in supine position. POSA is commonly defined as more
than twice as many respiratory events in the supine sleep po-
sition compared to non-supine sleep position [5–8].
Therapy for OSA generally starts with conservative treat-
ment, consisting of lifestyle changes such as weight reduction
and avoidance of alcohol, sedatives, and the supine sleeping
position, when applicable. Thereafter, current options include
continuous positive airway pressure (CPAP), oral appliance
therapy (OAT) and pharyngeal surgery [9–11]. CPAP is the
gold standard therapy for moderate to severe OSA, but adher-
ence to CPAP is often suboptimal, necessitating exploration of
other options [12]. Oral appliances (OA) are widely used in
mild to moderate OSA, and are associated with clinically rel-
evant decreases in the AHI [13], making them an increasingly
attractive first-line therapy option in these patients.
Vecchierini et al. reported OAT success rates of 40–70 and
78–81% in mild to moderate patients for an AHI to < 5/h
and for an AHI reduction of at least 50%, respectively [13].
However, adverse events such as tooth pain, changes in tooth
position resulting in a different occlusion and articulation, or
temporomandibular dysfunction can limit adherence to this
therapy [14, 15]. Surgery can be an option for patients who
are unresponsive, noncompliant, or desire a permanent treat-
ment for their OSA [16–18].
For POSA, alternatives include the use of specific treat-
ments designed to avoid the supine sleeping position.
However, the effectiveness of therapy with first generation
devices has been limited. For example, the Btennis ball-
technique^ is uncomfortable for patients to use and disrupts
sleep, leading to poor long-term adherence [19]. Next-
generation treatment options with active feedback and auto-
adapted treatment intensity to decrease discomfort and im-
prove compliance were introduced. These include active po-
sitional therapies like supine alarm devices and neck or chest-
worn vibrating devices [20, 21]. The Sleep Position Trainer
(SPT) is such a chest-worn device and it showed to signifi-
cantly reduce the average supine sleeping time (from 46 to
5%), the AHI to < 5/h in 48%, and an AHI reduction of at
least 50% in 71% of patients with mild or moderate POSA
[22]. Effectiveness and adherence were good, with an objec-
tive adherence rate (> 4 h of nightly use) of 64.4% after
6 months of treatment and improved sleep-related quality of
life [23]. Additionally, short-term results have recently been
published on the effectiveness of the SPT versus OAT, show-
ing equal efficacy in reducing the median AHI in patients with
mild to moderate POSA [24]. However, there are no data on
the use and effect of the SPT beyond 6 months. Therefore, we
aimed to study the longer-term efficacy and adherence of the
SPT (the intervention) in comparison to OAT (active compar-
ator). Hence, we hypothesized that the SPT would be more
efficacious in reducing the AHI compared to OAT in patients
with mild to moderate POSA. This paper investigated the
durability of the previously reported short-term effects of the
SPT with respect to efficacy, adherence, and quality of life,
after 12 months of follow-up.
Methods
Participants
Participants were eligible for enrollment if they had a diagno-
sis of mild-to-moderate POSA (AHI of 5–30) and spent 10–
90% of their total sleep time in the supine position during
baseline PSG. Exclusion criteria included inadequate denti-
tion for wearing an oral appliance, subjective snoring in the
lateral position, central sleep apnea, night or rotating shift
work, severe chronic heart disease, active psychiatric disease,
seizure disorders, medication usage for sleeping disorders,
muscular or joint injuries in the head, neck, or back area,
previous OAT or SPT usage, simultaneous use of other treat-
ment for OSA, reversible morphological upper airway abnor-
malities (e.g., enlarged tonsils), pregnancy, and coexisting
non-respiratory sleep disorders (e.g., insomnia, periodic limb
movement disorder, narcolepsy) that would compromise func-
tional sleep assessment. All participants underwent medical
and dental consultations, and a baseline PSG prior to the start
of the study.
Study design and oversight
The study was designed as a multicenter, prospective random-
ized controlled trial. Patients were recruited and followed at
the depar tments of Otolaryngology and Clinical
Neurophysiology at OLVG West Hospital, Amsterdam, and
at the department of oral and maxillofacial surgery at the
Academic Medical Center, Amsterdam. The institutional
Medical Ethics Committee of the OLVG West Hospital,
Amsterdam, and the Academic Medical Center Amsterdam
approved the protocol. The randomization sequence was gen-
erated by an independent clinical research unit using ALEA
software with a 1:1 allocation using maximum random block
sizes of 6 and stratification for smoking and body mass index
(BMI). Independent monitors verified the source data and
documentation.
Study treatments
The sleep position trainer (SPT-DEV-PX-11.08; NightBalance)
consists of a small lightweight device (72 × 35 × 10 mm; 25 g)
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worn across the chest using a neoprene strap (Fig. 1) [22]. The
SPT vibrates when a supine position is detected to prompt a
change in body position. Data storage on the device allows for
objective measurement of adherence to the therapy. Further
details on functionality of the SPTare described elsewhere [24].
As active comparator, the OAwas a custom-made duo-bloc
device (SomnoDent flex; SomnoMed) (Fig. 2). After adequate
assessment of the central relation and maximum protrusion,
the OA was set at 60% of maximum protrusion at baseline.
The OA was adjusted individually and advancement was ti-
trated using a standard protocol by the dentist, which was
described in greater detail elsewhere [24]. Objective adher-
ence was measured using a temperature-sensitive microsensor
with on-chip integrated read-out electronics (Theramon,
Handels- und Entwicklungsgeselschaft, Handelsagentur
Gschladt, Hargelsberg, Austria) with a sampling rate of one
measurement every 15 min. A recorded temperature of
> 30 °C indicated that the OAwas worn.
Outcome measures
The primary outcome was the change in OSA severity after
12 months compared with baseline. OSA severity was deter-
mined based on the AHI and the oxygen desaturation index
(ODI; the number of times per hour of sleep that the blood
oxygen level drops by ≥ 4% from baseline, according to the
prevailing definition at that time). These parameters were de-
termined from overnight PSG (Embla A10, Broomfield, CO,
USA) which records electroencephalogram (EEG) (FP2-C4/
C4-O2), electro-oculogram (EOG), electrocardiogram (ECG),
and submental and anterior tibial electromyogram (EMG).
Nasal airflow was measured by a nasal pressure cannula and
blood oxygen saturation by finger pulse oximetry. Straps con-
taining piezoelectric transducers recorded thoracoabdominal
motion, and a position sensor (Sleepsense, St Charles, IL,
USA) attached to the midline of the abdominal wall was used
to differentiate between supine, prone, right lateral, left lateral,
and upright positions. Recordings were manually scored by an
independent core laboratory using American Academy of Sleep
Medicine (AASM) 2012 scoring criteria [25]. Secondary out-
comes included additional polysomnographic variables, per-
centage of time spent sleeping in the supine position, AHI in
the supine and non-supine positions, and sleep efficiency. Self-
reported daytime sleepiness was assessed using the Epworth
Sleepiness Scale (ESS; score range 0–24, score ≥ 10 indicates
excessive daytime sleepiness). Disease-specific quality of life
was assessed with the Functional Outcomes of Sleep
Questionnaire (FOSQ-30; score range 5–20, higher scores in-
dicate better functioning). Adherence was defined as device
(SPT or OAT) usage for ≥ 4 h/night at least 5 days per week.
Follow-up
This paper aimed at testing the durability of treatment effect
after 12-month follow-up. Throughout the follow-up, patients
underwent repeat PSG at 3 and 12months, while using the SPT
or OAT. Patients completed the ESS and FOSQ-30 at baselineFig. 1 Sleep Position Trainer
Fig. 2 Oral appliance therapy, including a blue chip for measuring
adherence
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and after 3 and 12 months of therapy. Objective adherence and
medical evaluation (including heart rate and blood pressure
measured twice seated by two independent physicians with an
interval of 3 min) were also assessed at 3 and 12 months.
Adverse events
Adverse events were reported in accordance with the
International Conference of Harmonization ICH E2A guide-
lines (Good Clinical Practice) by the principal investigators
and evaluated by independent data monitors [26].
Statistical analysis
Power analysis resulted in a minimum sample size of 36 par-
ticipants per study arm (to reach a power of 80%). In order to
allow for dropout, the recruitment target was inflated to 49 per
group. The level for statistical significance was set atα = 0.05.
The statistical programming and analysis was performed
using IBM SPSS statistics version 24 (IBM Corp., Armonk.
NY,USA). Due to the proportion ofmissing data at 12months,
analyses were primarily conducted on a per-protocol (PP) ba-
sis. Additionally, illustrative worst-case and best-case
intention-to-treat (ITT) analyses were performed through im-
puting missing data through the Last-Observation-Carried-
Forward method.
Variables were summarized using descriptive statistics:
mean value with standard deviation for continuous symmetric
variables, median and interquartile range for continuous
skewed variables, and frequency with percentage for categor-
ical variables. For the primary outcome, repeated measures
ANOVA was performed to test for differences over time.
Thereafter, within-subject comparisons (patient progression
over time; paired) between continuous variables at baseline
and follow-up (3 and 12 months) and between the 3- and
12-month follow-ups were made using the paired t test (non-
skewed data) or the Wilcoxon signed rank test (skewed data).
Between-group difference tests (deltas baseline vs. follow-up)
were performed using an independent t test (non-skewed data)
or Mann-Whitney U test (skewed data). Both the between-
group and within-subject analyses were adjusted for multiple
comparisons using the Bonferroni correction.
Results
A total of 177 patients with mild to moderate POSA were
screened for eligibility (70.7% male, age 48.3 ± 10.1 years;
BMI 27.6 ± 3.8 kg/m2). Of these, 99 patients met all eligibility
criteria and were randomized to OAT (n = 51) or SPT (n = 48)
(Fig. 3). Baseline characteristics for these patients are shown in
Table 1 with comparison of the characteristics between
Bcompleters^ and Bdropouts.^ There was only a statistically
significant difference in blood pressure between the OAT and
SPT groups at baseline (Table 1). The total number of patients
receiving allocated treatment with OATand SPT, and complet-
ing 3 months’ follow-up was 36 and 45, respectively. Over the
remaining 9 months of follow-up, an additional seven patients
withdrew in the OAT group (one lost to follow-up and six
discontinued treatment due to adverse events [n = 2], lack of
efficacy [n = 3], or both adverse event and efficacy [n = 1])
(Fig. 3). In the SPT group, 2 patients were lost to follow-up and
14 discontinued treatment (lack of efficacy [n = 3], persistent
snoring [n = 4], adverse events [n = 3; 2 not related to SPT], or
other non-related reasons [n = 4]) (Fig. 3). A total of 58 patients
were eligible for per-protocol analysis after 12 months (Fig. 3).
Primary outcome
PP analysis showed that the AHI and ODI were significantly
reduced compared with baseline at both the 3- and 12-month
follow-up visits for both treatment groups, with no significant
between-group differences (Table 2). The absolute reductions
in AHI and ODI at 3 months were maintained at 12 months in
both groups (Table 2). ITTanalysis for the primary outcome is
provided in Table S1. The AHI reduced for more than 50% in
48.3 and 51.7% of SPT patients after 3 and 12months, respec-
tively. For the OAT group, this reduction was found in 48.3%
patients after 3 months and 55.2% patients after 12 months of
follow-up. The outcomes were not statistically different be-
tween the two treatment groups (P = 1.000 at 3 months and
P = 0.792 at 12 months). Alternatively, a reduction of the AHI
under 5/h for the 3- and 12-month follow-up was found in
34.5 and 41.4% of SPT patients and 41.4 and 51.7% of OAT
patients, respectively. These outcomes were also not signifi-
cantly different between the groups (P = 0.5888 at 3 months
and P = 0.430 at 12 months).
Durability of the treatment effect of both the SPT and OAT
groups was good (Fig. 4). There was a statistically significant
effect of time on the AHI under treatment (F(2, 56) = 65.97,
P < 0.001), with no significant between-group difference
(P = 0.592). For the reduction in AHI, stratification by OSA
severity at baseline (mild [n = 34) vs. moderate [n = 24]) was
performed (F(2, 54) = 102.39, P < 0.001). However, no
severity-related difference in reduction of AHI was observed
between the treatment arms (P = 0.200).
Secondary outcomes
Polysomnographic indices
Treatment with SPTwas associated with a significant decrease
in supine sleeping time (P < 0.001 vs. baseline after 3 and
12 months), but supine sleeping time was unchanged from
baseline in the OAT group (between-group difference,
P < 0.001) (Table 2). Supine AHI decreased to a similar extent
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in the two groups (Table 2). Sleep efficiency remained stable
over the 12-month follow-up, and no significant changes in
cardiovascular parameters were observed between the two
treatment groups (Table 2).
Adherence
Device usage and adherence were similar in the SPTand OAT
groups throughout the 12-month follow-up (Table 3 and S2).
The average usage per night was 5.2/h for SPT and 5.0/h for
OAT (P = 0.743). Median adherence per patient (≥ 4 h for
5 days/week) was 100% in the SPT group and 97.0% in the
OAT group (P = 0.598).
Subjective daytime sleepiness and sleep-related quality of life
Complete 12-month data from the ESS questionnaire were
available for 21/29 (72%) and 25/29 (86%) patients in the
SPT and OAT groups, respectively; corresponding values for
completion of the FOSQ were 12/29 (41%) and 13/29 (45%).
No significant changes in the ESS score and FOSQ score were
identified in either treatment group (Table 2).
Adverse events
A total of 114 device-related adverse events (AE) were reported
by 48 patients (82.8%) overall, 20 (69.0%) in the SPT group,
and 28 (96.6%) in the OAT group (Table 4). Overall, the most
common adverse events in both groups were persistent snoring
and persistent tiredness. A similar degree of persistent snoring
was reported for SPT and OAT; by 14 and 15 patients, respec-
tively. However, for an additional four SPT patients, persistent
snoring was a reason for dropping out of the study (Fig. 3). The
most common SPT-specific adverse events were being woken
by the vibration and no reaction to the vibration. In the OAT
group, the most common device-specific events were tooth
pain, temporomandibular dysfunction, and open bite. In pa-
tients treated with the SPT, no events necessitated a temporary
discontinuation of device use. For the OAT group, study treat-
ment was temporarily discontinued as a result of six events in a
total of five patients (17.2% of patients). The number of device-
Assessed for eligibility (n= 177) 
Excluded (n= 78) 
Not meeting inclusion criteria (n= 65) 
Declined to participate (n= 4) 
Other reasons (n= 9) 
Randomized to OAT (n= 51) 
(Intention-to-treat Cohort) 
Randomized (n= 99) 
Randomized to SPT (n= 48) 
(Intention-to-treat Cohort)
Did not receive allocated 
intervention (n= 15)  
 Withdrew consent (n=4) 
 Dental exclusion (n=5)* 
 Lost to follow-up (n=5) 
 AE (cardiac event), (n=1) 
Did not receive allocated 
intervention (n=3)  
 Withdrew consent (n=3) 
Completed 3-month Follow-up (n=36) Completed 3-month Follow-up (n=45) 
Lost to Follow-up (n= 1)  
 Moved abroad (n=1) 
Discontinued Intervention 
 AE (efficacy**) (n=3) 
 AE (tooth pain) (n=2) 
 AE (tooth pain) and efficacy 
(n=1) 
Lost to Follow-up (n= 2)  
 Moved abroad (n=1) 
 Other (n=1) 
Discontinued Intervention 
 AE (efficacy**) (n=3) 
 AE (persistent snoring) (n=4) 
 AE (other) (n=3)*** 
 Other (n=4) 
Completed 12-month Follow-up (n= 29) 
(Per-protocol Analysis) 
Completed 12-month Follow-up (n= 29) 
(Per-protocol Analysis) 
Fig. 3 Flow of patients through
the study. AE, adverse event;
OAT, oral appliance therapy; SPT,
Sleep Position Trainer. *Although
insufficient dental status was an
exclusion criterion, a dentist
checked this through regular
physical examination. Some
dental problems were only
visualized after the
orthopantomography was made.
** Efficacy: persistent apneas/
AHI. *** Adverse events; one
related events (joint problems due
to wearing SPT), two non-related
events (one patient had nasal
problems and was not motivated
to continue and one patient had
broken ribs due to an accident and
did not want to continue)
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Sleep Breath
specific adverse events (vs. non-specific events) was higher in
the OAT group (44 vs. 8 in the SPT group; P < 0.001). No
statistical difference was found in the duration (in days) of
adverse events (P = 0.830) between the groups.
Discussion
The results of this study in patients with POSA showed that
the beneficial effects of both the SPT and OAT observed at
3 months’ persisted through 12 months of device use. The
SPT improved sleep apnea to a similar extent as OAT and
was associated with high adherence rates. This is the first
long-term, randomized controlled trial comparing positional
therapy using the SPT with OAT for the treatment of POSA.
These findings are consistent with previous short-term data
on the SPT [22, 27] and confirm that benefits are maintained
over a longer-term follow-up. It is important to assess OSA
therapies over longer periods of time because many, including
CPAP, show reduced adherence over time. When adherence is
defined as device usage for > 4 h/night, 46–83% of CPAP
users are nonadherent [12]. Objective data on use of OAT
have shown that 83% of patients used the device regularly
[28]. Adherence rates for OAT in our study were similar, and
SPT device usage was also of a similar magnitude. In this
study, SPT had similar long-term efficacy to OAT and was
associated with consistently high levels of adherence over
12 months’ follow-up, highlighting the potential clinical util-
ity of the SPT in everyday practice.
Analysis of patients not allocated to treatment and those
withdrawn from the study provides some insight into optimal
patient selection and the challenges faced with each therapy.
No significant difference between completers and dropouts
Table 4 Adverse events
Total SPT OAT
Number of subjects (%) 58 (100) 29 (100) 29 (100)
Reporting at least 1 AE (%) 48 (82.8) 20 (69.0) 28 (96.6)
Frequency of events (%) 114 (100) 37 (100) 77 (100)
Persistent snoring (%) 29 (25.4) 14 (37.8) 15 (19.5)
Persistent tiredness (%) 21 (18.4) 7 (18.9) 14 (18.2)
Persistent apneas (%) 1 (0.9) 1 (2.7) 0 (0.0)
Comfort problems (%) 7 (6.1) 5 (13.5) 2 (2.6)
Other (%) 4 (3.5) 2 (5.4) 2 (2.6)
OAT
Tooth pain (%) 21 (18.4) 21 (27.3)
TMD (%) 9 (7.9) 9 (11.7)
Open bite (%) 7 (6.1) 7 (9.1)
Dry mouth (%) 4 (3.5) 4 (5.2)
Hypersalivation (%) 1 (0.9) 1 (1.3)
Dental fracture (%) 1 (0.9) 1 (1.3)
Oral lesions (%) 1 (1.3) 1 (1.3)
SPT
Woken up by vibration (%) 4 (3.5) 4 (10.8)
No reaction to vibration (%) 4 (3.5) 4 (10.8)
AE adverse event, OAT oral appliance therapy, SPT Sleep Position
Trainer, TMD temporomandibular dysfunction
Fig. 4 Durability of effects on the apnea-hypopnea index (AHI) over
time in the Sleep Position Trainer (SPT) and oral appliance therapy
(OAT) groups (ANOVA repeated measures)
Table 3 Objective adherence and
device usage (per-protocol
analysis)
SPT (n = 29) OAT (n = 28) P value
Total nights 365.0 (362.5–365.0) 356.5 (275.8–373.5) 0.805a
Total nights with adherence > 4 h 237.6 ± 96.3 239.9 ± 96.1 0.930b
Average hours of use per night 5.2 ± 2.2 5.0 ± 2.0 0.743b
Adherence > 4 h on 7 days in a week, % patients 82.0 (47.0–90.5) 79.8 (59.7–97.4) 0.314a
Adherence > 4 h on 5 days in a week, % patients 100.0 (65.5–100.0) 97.0 (79.9–100.0) 0.598a
Values are mean ± standard deviation or median (interquartile range). One patient missing data in OAT group
OAT oral appliance therapy, SPT Sleep Position Trainer
aMann-Whitney test
b Independent T test
Sleep Breath
was found in baseline characteristics (Table 1). Most dropouts
in the OAT group were seen before the start of treatment.
Dentition played an important role in the initiation to treat-
ment, and prevented device use in 33% of OAT patients who
did not start the allocated treatment. It has been reported that
dental limitation might preclude the use of OAT in up to 34%
of all OSA cases [29]. In our study, the rate of adverse events
over the first year of therapy was higher in the OAT group than
in the SPT group. However, more subjects discontinued use of
the SPT due to AEs between the 3- and 12-month assessments
(14 vs. 6 for OAT), although the number of completers was the
same in both groups (n = 29). Within the non-completers, the
rate of persistent AHI was similar between groups as reason
for dropout. Tooth pain was mentioned in the OAT group,
while in the SPT group persistent snoring, joint problems,
nasal problems, and broken ribs were reported as reason for
dropout. Due to the mechanism of action of the SPT device,
AHI and continuous snoring in the lateral position are not
decreased. Just as dentition may play a role in patient selection
for OAT, high lateral AHI and/or lateral snoring may be fac-
tors that identify patients less suitable for the SPT. Knowledge
of the advantages, disadvantages, and adverse effects with
each therapy can help guide clinicians to proper individual
therapy selection and follow-up regimes that maximize adher-
ence and long-term outcomes.
Study limitations
The main limitation of this study was the slightly higher than
expected observed dropout rate at 3 months. We mitigated this
by performing additional ITT analyses on the primary out-
come, using the Last-Observation-Carried-Forward method.
The relatively low number of patients at 12 months could also
be raised as a concern; however, the 20% dropout rate was
predicted for the 3-month assessment as the primary outcome,
and therefore more dropout would have been expected at
12 months. Regardless, we have included a sensitivity analy-
sis to demonstrate the robustness of our results to the high
dropout rate at 3 and 12 months. The best and worst case
scenarios demonstrate the maximum and minimum bounds
for the treatment effects (respectively) under different missing
mechanisms for the treatment and control groups. The best
case scenario assumed a 50% decrease in AHI from baseline
for patients with missing data in the SPT group compared to a
0% change in AHI from baseline for patients with missing
data in the OAT group. The worst case scenario assumed a
0% change in AHI from baseline for patients with missing
data in the SPT group compared to a 50% decrease in AHI
from baseline for patients with missing data in the OAT group.
The results from these analyses demonstrate the extremes that
would be expected if the missingness in the SPT and OAT
groups occurred for contrasting reasons (Table S3).
Conclusion
The results of this study show that the efficacy of SPT was
maintained over 12 months of therapy, and was comparable to
that of OAT in patients with mild to moderate POSA.
Adherence to both treatment modalities was high, and similar
in the two groups. Good long-term adherence can make an
important contribution to the ongoing effectiveness of treat-
ment in clinical practice.
Funding information Foundation Nuts Ohra for execution of the study.
Compliance with ethical standards
Conflict of interest M.H.T. de Ruiter, L.B.L. Benoist and Prof. Dr. J.
de Lange state that they have no conflicts of interest to declare. Prof. Dr.
N. de Vries is member of the Medical Advisory Board of NightBalance,
consultant to Philips Healthcare and Olympus, researcher for Inspire
Medical Systems, member of ReVent’s Medical Advisory Board, and
has shares in NightBalance and ReVent.
Ethical approval All procedures performed in studies involving hu-
man participants were in accordance with the ethical standards of the
institutional and/or national research committee and with the 1964
Helsinki declaration and its later amendments or comparable ethical
standards.
References
1. Senaratna CV, Perret JL, Lodge C, Lowe A, Campbell BE,
Matheson MC, Hamilton GS, Dharmage SC (2016) Prevalence of
obstructive sleep apnea in the general population: a systematic re-
view. Sleep Med Rev. https://doi.org/10.1016/j.smrv.2016.07.002
2. Heinzer R, Vat S, Marques-Vidal P, Marti-Soler H, Andries D,
Tobback N, Mooser V, Preisig M, Malhotra A, Waeber G,
Vollenweider P, Tafti M, Haba-Rubio J (2015) Prevalence of
sleep-disordered breathing in the general population: the
HypnoLaus study. Lancet Respir Med 3(4):310–318. https://doi.
org/10.1016/S2213-2600(15)00043-0
3. (1999) Sleep-related breathing disorders in adults: recommenda-
tions for syndrome definition and measurement techniques in clin-
ical research. The report of an American Academy of Sleep
Medicine Task Force. Sleep 22 (5):667–689. https://doi.org/10.
1093/sleep/22.5.667
4. Strollo PJ Jr, Rogers RM (1996) Obstructive sleep apnea. N
Engl J Med 334(2):99–104. https: / /doi .org/10.1056/
NEJM199601113340207
5. Cartwright RD (1984) Effect of sleep position on sleep apnea se-
verity. Sleep 7(2):110–114
6. Oksenberg A, Silverberg DS, Arons E, RadwanH (1997) Positional
vs nonpositional obstructive sleep apnea patients: anthropomor-
phic, nocturnal polysomnographic, and multiple sleep latency test
data. Chest 112(3):629–639
7. Richard W, Kox D, den Herder C, Laman M, van Tinteren H, de
Vries N (2006) The role of sleep position in obstructive sleep apnea
syndrome. Eur Arch Otorhinolaryngol 263(10):946–950. https://
doi.org/10.1007/s00405-006-0090-2
8. MadorMJ, Kufel TJ, Magalang UJ, Rajesh SK,Watwe V, Grant BJ
(2005) Prevalence of positional sleep apnea in patients undergoing
Sleep Breath
polysomnography. Chest 128(4):2130–2137. https://doi.org/10.
1378/chest.128.4.2130
9. Hoekema A, Stegenga B, De Bont LG (2004) Efficacy and co-
morbidity of oral appliances in the treatment of obstructive sleep
apnea-hypopnea: a systematic review. Crit Rev Oral Biol Med
15(3):137–155
10. Lim J, Lasserson TJ, Fleetham J, Wright J (2004) Oral appliances
for obstructive sleep apnoea. Cochrane Database Syst Rev 4:
CD004435. https://doi.org/10.1002/14651858.CD004435.pub2
11. Sawyer AM, Gooneratne NS, Marcus CL, Ofer D, Richards KC,
Weaver TE (2011) A systematic review of CPAP adherence across
age groups: clinical and empiric insights for developing CPAP ad-
herence interventions. Sleep Med Rev 15(6):343–356. https://doi.
org/10.1016/j.smrv.2011.01.003
12. Weaver TE, Grunstein RR (2008) Adherence to continuous positive
airway pressure therapy: the challenge to effective treatment. Proc
Am Thorac Soc 5(2):173–178. https://doi.org/10.1513/pats.
200708-119MG
13. Vecchierini M, Attali V, Collet J, d’Ortho M, El Chater P, Kerbrat J,
Leger D,Monaca C,Monteyrol P, Morin L, Mullens E, Pigearias B,
Meurice J, investigator ftO (2016) A custom-made mandibular re-
positioning device for obstructive sleep apnoea–hypopnoea syn-
drome: the ORCADES study. Sleep Med 19:131–140
14. Doff MH, Finnema KJ, Hoekema A, Wijkstra PJ, de Bont LG,
Stegenga B (2013) Long-term oral appliance therapy in obstructive
sleep apnea syndrome: a controlled study on dental side effects.
Clin Oral Investig 17(2):475–482. https://doi.org/10.1007/s00784-
012-0737-x
15. Doff MH, Veldhuis SK, Hoekema A, Slater JJ, Wijkstra PJ, de Bont
LG, Stegenga B (2012) Long-term oral appliance therapy in ob-
structive sleep apnea syndrome: a controlled study on temporoman-
dibular side effects. Clin Oral Investig 16(3):689–697. https://doi.
org/10.1007/s00784-011-0555-6
16. Caples SM, Rowley JA, Prinsell JR, Pallanch JF, Elamin MB, Katz
SG, Harwick JD (2010) Surgical modifications of the upper airway
for obstructive sleep apnea in adults: a systematic review and meta-
analysis. Sleep 33(10):1396–1407
17. Strollo PJ Jr, Soose RJ, Maurer JT, de Vries N, Cornelius J,
Froymovich O, Hanson RD, Padhya TA, Steward DL, Gillespie
MB, Woodson BT, Van de Heyning PH, Goetting MG,
Vanderveken OM, Feldman N, Knaack L, Strohl KP, Group ST
(2014) Upper-airway stimulation for obstructive sleep apnea. N
Engl J Med 370(2):139–149. https://doi.org/10.1056/
NEJMoa1308659
18. Zaghi S, Holty JE, Certal V, Abdullatif J, Guilleminault C, Powell
NB, Riley RW, Camacho M (2016) Maxillomandibular advance-
ment for treatment of obstructive sleep apnea: a meta-analysis.
JAMA Otolaryngol Head Neck Surg 142(1):58–66. https://doi.
org/10.1001/jamaoto.2015.2678
19. Bignold JJ, Deans-Costi G, Goldsworthy MR, Robertson CA,
McEvoy D, Catcheside PG, Mercer JD (2009) Poor long-term pa-
tient compliance with the tennis ball technique for treating position-
al obstructive sleep apnea. J Clin Sleep Med 5(5):428–430
20. van Maanen JP, Richard W, Van Kesteren ER, Ravesloot MJ,
Laman DM, Hilgevoord AA, de Vries N (2012) Evaluation of a
new simple treatment for positional sleep apnoea patients. J Sleep
Res 21(3):322–329. https://doi.org/10.1111/j.1365-2869.2011.
00974.x
21. Bignold JJ, Mercer JD, Antic NA, McEvoy RD, Catcheside PG
(2011) Accurate position monitoring and improved supine-
dependent obstructive sleep apnea with a new position recording
and supine avoidance device. J Clin Sleep Med 7(4):376–383.
https://doi.org/10.5664/JCSM.1194
22. van Maanen JP, Meester KA, Dun LN, Koutsourelakis I, Witte BI,
Laman DM, Hilgevoord AA, de Vries N (2013) The sleep position
trainer: a new treatment for positional obstructive sleep apnoea.
Sleep Breath 17(2):771–779. https://doi.org/10.1007/s11325-012-
0764-5
23. van Maanen JP, de Vries N (2014) Long-term effectiveness and
compliance of positional therapy with the sleep position trainer in
the treatment of positional obstructive sleep apnea syndrome. Sleep
37(7):1209–1215. https://doi.org/10.5665/sleep.3840
24. Benoist L, de Ruiter M, de Lange J, de Vries N (2017) A random-
ized, controlled trial of positional therapy versus oral appliance
therapy for position-dependent sleep apnea. Sleep Med 34:109–
117. https://doi.org/10.1016/j.sleep.2017.01.024
25. Berry RB, Brooks R, Gamaldo CE, Harding SM, Marcus C,
Vaughn B (2012) The AASM manual for the scoring of sleep and
associated events, Rules, terminology and technical specifications.
American Academy of Sleep Medicine, Darien
26. Bhuiyan P, Rege N (2001) ICH Harmonised Tripartite Guideline:
guideline for good clinical practice. J Postgrad Med 47:45–50
27. Eijsvogel MM, Ubbink R, Dekker J, Oppersma E, de Jongh FH,
van der Palen J, Brusse-Keizer MG (2015) Sleep position trainer
versus tennis ball technique in positional obstructive sleep apnea
syndrome. J Clin Sleep Med 11(2):139–147. https://doi.org/10.
5664/jcsm.4460
28. Dieltjens M, Braem MJ, Vroegop AV, Wouters K, Verbraecken JA,
De Backer WA, Van de Heyning PH, Vanderveken OM (2013)
Objectively measured vs self-reported compliance during oral ap-
pliance therapy for sleep-disordered breathing. Chest 144(5):1495–
1502. https://doi.org/10.1378/chest.13-0613
29. Petit FX, Pepin JL, Bettega G, Sadek H, Raphael B, Levy P (2002)
Mandibular advancement devices: rate of contraindications in 100
consecutive obstructive sleep apnea patients. Am J Respir Crit Care
Med 166(3):274–278. https://doi.org/10.1164/rccm.2008167
30. https://doi.org/10.1093/sleep/22.5.667
31. (2001) ICH harmonized tripartite guideline: Guideline for Good
Clinical Practice. J Postgrad Med 47:45–50
Sleep Breath
